AstraZeneca Prevails In Trial Over Diabetes Drug Patent

Law360, New York (February 3, 2017, 6:41 PM EST) -- A Delaware federal judge ruled Thursday that AstraZeneca's patents covering its $3.5 billion diabetes drugs Onglyza‎ and Kombiglyze XR were not invalid for being obvious, though he denied the pharmaceutical company's request for attorneys’ fees in its suit against generic drug makers.

U.S. District Judge Gregory M. Sleet ruled Thursday that Wockhardt BIO AG, Mylan Pharmaceuticals Inc., Amneal Pharmaceuticals LLC and three other generics makers failed to show that two asserted claims of AstraZeneca AB’s U.S. Patent Number RE44,186 are invalid as obvious in light of...
To view the full article, register now.